Suckling Colin J, Hunter Iain S, Scott Fraser J
Department of Pure & Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL, UK.
Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Future Drug Discov. 2022 Apr;4(1):FDD73. doi: 10.4155/fdd-2022-0001. Epub 2022 May 5.
The standard drug discovery paradigm of single molecule - single biological target - single biological effect is perhaps particularly unsuitable for anti-infective drug discovery. This is due to the rapid evolution of resistance likely to be observed with single target drugs. Multitargeted anti-infective drugs are likely to be superior due to their lower susceptibility to target-related resistance mechanisms. Strathclyde minor groove binders are a class of compounds which have been developed by adopting the multitargeted anti-infective drugs paradigm, and their effectiveness against a wide range of pathogenic organisms is discussed. The renaming of this class to Strathclyde nucleic acid binders is also presented due to their likely targets including both DNA and RNA.
单分子-单生物靶点-单生物效应这一标准的药物发现模式可能尤其不适用于抗感染药物的发现。这是因为单靶点药物可能会迅速出现耐药性进化。多靶点抗感染药物可能更具优势,因为它们对靶点相关耐药机制的敏感性较低。斯特拉斯克莱德小沟结合剂是一类采用多靶点抗感染药物模式开发的化合物,并讨论了它们对多种致病生物的有效性。由于它们可能的靶点包括DNA和RNA,因此也提出了将此类重新命名为斯特拉斯克莱德核酸结合剂。